GNT induction treatment for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage III or IVB nasopharyngeal cancer that is either keratinizing or non-keratinizing squamous cell type.
- You are able to receive radiation and chemotherapy together as your main treatment.
- Your overall health allows you to perform daily activities (ECOG score 0-1).
- You have at least one tumor that can be measured, and your blood counts, kidney, and liver function are within certain normal ranges.
- You haven't had prior immunotherapy or targeted therapy for cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This Phase 3 trial tests giving chemotherapy first, then either radiation alone or chemotherapy together with radiation. It aims to improve treatment control for people with newly diagnosed, advanced nasopharyngeal cancer.
This trial tests a new combination of three drugs (TPC, apatinib, and camrelizumab) against the standard two-drug regimen (GP plus camrelizumab) for people with high-risk nasopharyngeal carcinoma that has spread to neck lymph nodes. The goal is to see if the three-drug combination works better and is safe.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.